Supported by 1,500 peer-reviewed studies, Bertilimumab is a first-in-class antibody which targets and lowers eotaxin-1 levels. It is being studied to see if it will improve outcomes in patients with autoimmune diseases that do not have therapies or the therapies have severe limitations, such as Bullous Pemphigoid and Crohn's & Colitis Read More 

Latest News

PRESS RELEASE January 10, 2017

Immune Pharmaceuticals Will Request an Appeal to Regain Compliance with Nasdaq’s Minimum Bid Price Rule | Read more 


EVENT January 4, 2017

R&D Trends: What’s Changed in the Pharma Pipeline? | Read more 


January 3, 2017

Strategic Focus and Partnerships: Part 1 | Read more 


See All News 

Upcoming Events

No upcoming events found

See All Events